Lucemyra scripts taking off!


anonymous

Guest
My buddy sent me the script data (he got it from SymphonY, looks like Lucemyra is quickly becoming a pretty good addition to the bag!
Gives us a legit reason to come back to GP for a quick visit.

8/17 28
8/24 40
8/31 52
9/07 46
9/14 60
9/21 79
9/28 73
10/05 95
 




Yeah those are national / week
Nothing huge but good trend
To put in context Relistor only does like 1,500 Rx/wk so Lucemyra doing 100 a couple weeks into launch is pretty solid.
 


My buddy sent me the script data (he got it from SymphonY, looks like Lucemyra is quickly becoming a pretty good addition to the bag!
Gives us a legit reason to come back to GP for a quick visit.

8/17 28
8/24 40
8/31 52
9/07 46
9/14 60
9/21 79
9/28 73
10/05 95

Rx up again this week:
8/17 28
8/24 40
8/31 52
9/07 46
9/14 60
9/21 79
9/28 73
10/05 95
10/12 119
 


Rx up again this week:
8/17 28
8/24 40
8/31 52
9/07 46
9/14 60
9/21 79
9/28 73
10/05 95
10/12 119

Bigger jump in Rx this week, momentum looking really good:
8/17 28
8/24 40
8/31 52
9/07 46
9/14 60
9/21 79
9/28 73
10/05 95
10/12 119
10/19 104
10/26 132
11/02 128
11/09 168

In a couple months Lucemyra already ~10% the size of Relistor franchise! Sells for a similar price.
 






It depends on who you ask. Great product but The product is a hard product to move and takes more time than I think it’s worth. Lots of effort for what josh says is $10M in 2019 sales. I find it hard to fathom why we are taking so much time to sell it and it’s in a high position in our bag with no room to move it lower. Not sure how this helps us grow salix when patent risks will cost us $200M over next 2 years plus cosmos reps are taking some of our turf with off label promotions.
 


Script update - still ramping up very nicely. Now well > 10% the size of Relistor.

Bigger jump in Rx this week, momentum looking really good:
8/17 28
8/24 40
8/31 52
9/07 46
9/14 60
9/21 79
9/28 73
10/05 95
10/12 119
10/19 104
10/26 132
11/02 128
11/09 168
11/16 144
11/23 131
11/30 157
12/7 189
 





Write your reply...